Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 2,861 full-time employees. The company went IPO on 2014-03-03. The firm operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. Its Generic Pharmaceuticals segment consists of a product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays.

Industry: Pharmaceutical Preparations Peers: AVADEL PHARMACEUTICALS PLC GH Research PLC /entities/itrm Jazz Pharmaceuticals PLC Keenova Therapeutics plc Nabriva Therapeutics plc Perrigo Company PLC